Clinical trials: Breast Cancer, Breast Neoplasms
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
Breast Carcinoma, Breast Cancer
Diffusion Tensor Imaging in Predicting Development of Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer (CIPN)
This pilot early phase I trial studies how well diffusion tensor imaging works in predicting development of chemotherapy induced peripheral neuropathy in patients with breast cancer.
- Conditions
- Breast Carcinoma, Breast Cancer, Neuropathy;Peripheral, Neuropathy
- Trial name
- CIPN (NCT03365895)
- Testing
- Diffusion Tensor Imaging, Laboratory Biomarker Analysis, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Arizona
Breast Neoplasms
Trial of Tomotherapy in Breast Cancer
Tomotherapy is a new radiation therapy system that uses an integrated CT scanner during delivery of radiation treatment to improve the accuracy of the treatment.
- Trial name
- TomoBreast (NCT00459628)
- Testing
- Conventional radiotherapy, Tomotherapy
- Where
- Belgium
- Volunteers
- 118 people
- Sponsor
- Vrije Universiteit Brussel
Non Small Cell Lung Cancer, Breast Cancer
Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer.
- Conditions
- Non Small Cell Lung Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- PTC-IMPACT (NCT06227728)
- Where
- 2 sites in Vietnam
- Volunteers
- 50 people
- Sponsor
- Gene Solutions
Liver Cancer, Lung Cancer
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion…
- Conditions
- Liver Cancer, Lung Cancer, Breast Cancer, Colo-rectal Cancer
- Trial name
- NCT04842812
- Testing
- TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
This randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery.
- Conditions
- Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
- Trial name
- NCT00861705
- Testing
- Bevacizumab, Carboplatin, Cyclophosphamide
- Where
- 448 sites in United States
- Volunteers
- 454 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET
To investigate parameters based on 18F-FES-PET/CT so as to estimate the outcome of palbociclib combined with endocrine therapy in patients with HR+/HER2-MBC.
- Trial name
- NCT04992156
- Testing
- Palbociclib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Metastatic Breast Cancer, Recurrent Breast Cancer
Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1)
To determine the maximum tolerated dose and/or maximum attainable dose of a vaccine consisting of adenovector expressing rat Her-2/neu in patients with metastatic or locally recurrent breast cancer.
- Trial name
- NCT00307229
- Testing
- adenoviral vector encoding rat Her-2/neu
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors
This trial studies how well a diabetes prevention program (METFIT) works in reducing insulin resistance in stage I-III breast cancer survivors.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04560439
- Testing
- Dietary Intervention
- Sponsor
- City of Hope Medical Center
Breast Cancer, Leptomeningeal Metastases
Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer
The purpose of this study is to evaluate the impact of Depocyte® IT combined with the systemic standard treatment in terms of clinical and/or radiological neuromeningeal progression free survival (SSPN)
- Trial name
- DEPOSEIN (NCT01645839)
- Testing
- Liposomal Cytarabine
- Where
- 10 sites in France
- Volunteers
- 74 people
- Sponsor
- Centre Oscar Lambret
Breast Cancer
Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer
This single-arm study is designed to test the hypothesis that a six-month intermittent fasting (IF) intervention is feasible for patients to adhere to and improves health-related quality of life while subjects are on adjuvant…
- Trial name
- NCT06106477
- Testing
- Intermittent Fasting
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical College of Wisconsin
Alopecia, Breast Cancer
Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants
RATIONALE: Bimatoprost ophthalmic solution may help increase eyebrow and eyelash growth in patients who have undergone chemotherapy.
- Trial name
- NCT00999557
- Testing
- bimatoprost ophthalmic solution
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer, Lung Cancer
A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.
This study will assess the effectiveness of a natural nutraceutical in treating the known side effects of chemotherapeutic agents in cancer patients.
- Conditions
- Breast Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT05137067
- Testing
- Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell), Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Optimal Health Research
Breast Cancer
A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast
The overarching purpose of this study is to determine if the mainstay chemotherapeutic regimens represented by several genotoxic agents including but not limited to Cyclophosphamide, Doxorubicin, Epirubicin, Fluorouracil and…
- Trial name
- COC-IDCB (NCT02897700)
- Testing
- Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate, cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM)
- Where
- 3 sites in China
- Volunteers
- 300 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Breast Neoplasms
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic.
- Trial name
- NCT07060807
- Testing
- Patritumab deruxtecan, Paclitaxel, Nab-paclitaxel
- Where
- 205 sites in United States, Argentina and 24 more
- Volunteers
- 1,000 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Adjuvant Treatment Recommendation and Oncotype DX® in Early Breast Cancer
Oncotype DX® is likely to become more widely used in Europe as well as in Switzerland. The test is currently not reimbursed by the Swiss health insurances.
- Trial name
- NCT01926964
- Where
- 19 sites in Switzerland
- Volunteers
- 229 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer, NSCLC
Docetaxel Ethanol-induced Symptoms; The Incidence and Risk Forecating Factor
To determine the incidence and risk factors of ethanol-induced symptoms, this multicenter, prospective, observational study is designed to include patients in Korea who are receiving chemotherapy with ethanol-containing docetaxel…
- Conditions
- Breast Cancer, NSCLC, Prostate Cancer, Head and Neck Cancer
- Trial name
- DETECT (NCT04545632)
- Where
- South Korea
- Volunteers
- 458 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Expanded Access to ANG1005 for Individual Patients
This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient…
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases, Leptomeningeal Carcinomatosis
- Trial name
- NCT02755987
- Testing
- ANG1005
- Where
- 2 sites in United States
- Sponsor
- Angiochem Inc
Breast Cancer, Breast Neoplasms
Supervised Exercise in Women With Breast Cancer
This pilot study examines the effects of a 14-week supervised, individualized physical exercise programme on psychological, motivational, and physical outcomes in women recently diagnosed with breast cancer who are undergoing…
- Trial name
- NCT07843121
- Testing
- Supervised individualized exercise programme
- Where
- Spain
- Volunteers
- 16 people
- Sponsor
- University of Extremadura
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
- Trial name
- NCT06876714
- Testing
- Trastuzumab (Herceptin), Pertuzumab, Echocardiography
- Where
- 702 sites in United States, Puerto Rico
- Volunteers
- 1,524 people
- Sponsor
- Alliance for Clinical Trials in Oncology
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.